GlassScriptPhysician profile
Mina Gendy
NPI 1811417868
$2,549.32
in general payments reported to CMS, 2019-2025
20 companies · $510 in 2025
The $510 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $673 · 2022: $606 · 2023: $427 · 2024: $333 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013 · Education: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.84 |
| Education | $256.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $794.56 | 2021-2023 | Padcev, Adcetris |
| Janssen Biotech, INC. | $309.72 | 2021-2024 | Darzalex, Tecvayli |
| Takeda Pharmaceuticals U.S.A., INC. | $194.70 | 2021 | |
| Pfizer INC. | $180.81 | 2024-2025 | |
| Genzyme Corporation | $143.77 | 2022 | |
| Taiho Oncology, INC. | $138.95 | 2024-2025 | |
| Astellas Pharma US INC | $117.85 | 2025 | Vyloy |
| Astrazeneca Pharmaceuticals LP | $116.60 | 2022-2025 | Enhertu |
| Abbvie INC. | $102.90 | 2021 | |
| Novartis Pharmaceuticals Corporation | $95.95 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $90.78 | 2024-2025 | Opdualag, Opdivo |
| Merck Sharp & Dohme LLC | $55.11 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Exelixis INC. | $37.69 | 2024-2025 | Cabometyx |
| Gilead Sciences, INC. | $34.52 | 2025 | Trodelvy |
| Daiichi Sankyo INC. | $31.94 | 2025 | Datroway, Enhertu |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.83 | 2021 | |
| Sanofi-Aventis U.S. LLC | $26.45 | 2022 | |
| Grifols USA, LLC | $18.39 | 2025 | Gamunex-C |
| Genentech USA, INC. | $17.23 | 2025 | Polivy |
| Incyte Corporation | $14.57 | 2025 | Jakafi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mina Gendy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.